Filtered By:
Drug: Zetia
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 236 results found since Jan 2013.
Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD?
J Fam Pract. 2023 Jun;72(5):227-229. doi: 10.12788/jfp.0610.ABSTRACTYES. In patients with known cardiovascular disease (CVD), ezetimibe with a statin decreases major adverse cardiovascular events (MACE) but has no effect on all-cause and cardiovascular mortality, compared to a statin alone (strength of recommendation [SOR], A; meta-analysis of randomized controlled trials [RCTs] including 1 large RCT). In adults with atherosclerotic CVD (ASCVD), the combination of ezetimibe and a moderate-intensity statin (rosuvastatin 10 mg) was noninferior at decreasing cardiovascular death, major cardiovascular events, and nonfatal stro...
Source: The Journal of Family Practice - June 20, 2023 Category: Practice Management Authors: Vinay Reddy James Allison Anne Mounsey Source Type: research
Position of the Polish Cardiac Society on therapeutic targets for LDL cholesterol concentrations in secondary prevention of myocardial infarctions
Kardiol Pol. 2023 Jul 25. doi: 10.33963/KP.a2023.0162. Online ahead of print.ABSTRACTCardiovascular diseases account for 43% of deaths in Poland. The COVID-19 pandemic increased the number of cardiovascular deaths by as much as 16.7%. Lipid metabolism disorders are observed in about 20 million Poles. Lipid disorders are usually asymptomatic, they cause a significant increase in the risk of cardiovascular diseases. Up to 20% of patients who experience an acute coronary syndrome (ACS) may experience a recurrence of a cardiovascular event within a year, and up to 40% of these patients may be re-hospitalized. Within 5 years af...
Source: Polish Heart Journal - July 25, 2023 Category: Cardiology Authors: Przemys ław Mitkowski Adam Witkowski Janina St ępińska Maciej Banach Piotr Jankowski Mariusz G ąsior Krystian Wita Stanis ław Bartuś Pawe ł Burchardt Micha ł M Farkowski Marek Gierlotka Robert Gil Przemys ław Leszek Maciej Sterli ński Piotr Szym Source Type: research
Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD?
J Fam Pract. 2023 Jun;72(5):227-229. doi: 10.12788/jfp.0610.ABSTRACTYES. In patients with known cardiovascular disease (CVD), ezetimibe with a statin decreases major adverse cardiovascular events (MACE) but has no effect on all-cause and cardiovascular mortality, compared to a statin alone (strength of recommendation [SOR], A; meta-analysis of randomized controlled trials [RCTs] including 1 large RCT). In adults with atherosclerotic CVD (ASCVD), the combination of ezetimibe and a moderate-intensity statin (rosuvastatin 10 mg) was noninferior at decreasing cardiovascular death, major cardiovascular events, and nonfatal stro...
Source: The Journal of Family Practice - June 20, 2023 Category: Practice Management Authors: Vinay Reddy James Allison Anne Mounsey Source Type: research
Position of the Polish Cardiac Society on therapeutic targets for LDL cholesterol concentrations in secondary prevention of myocardial infarctions
Kardiol Pol. 2023 Jul 25. doi: 10.33963/KP.a2023.0162. Online ahead of print.ABSTRACTCardiovascular diseases account for 43% of deaths in Poland. The COVID-19 pandemic increased the number of cardiovascular deaths by as much as 16.7%. Lipid metabolism disorders are observed in about 20 million Poles. Lipid disorders are usually asymptomatic, they cause a significant increase in the risk of cardiovascular diseases. Up to 20% of patients who experience an acute coronary syndrome (ACS) may experience a recurrence of a cardiovascular event within a year, and up to 40% of these patients may be re-hospitalized. Within 5 years af...
Source: Polish Heart Journal - July 25, 2023 Category: Cardiology Authors: Przemys ław Mitkowski Adam Witkowski Janina St ępińska Maciej Banach Piotr Jankowski Mariusz G ąsior Krystian Wita Stanis ław Bartuś Pawe ł Burchardt Micha ł M Farkowski Marek Gierlotka Robert Gil Przemys ław Leszek Maciej Sterli ński Piotr Szym Source Type: research
Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD?
J Fam Pract. 2023 Jun;72(5):227-229. doi: 10.12788/jfp.0610.ABSTRACTYES. In patients with known cardiovascular disease (CVD), ezetimibe with a statin decreases major adverse cardiovascular events (MACE) but has no effect on all-cause and cardiovascular mortality, compared to a statin alone (strength of recommendation [SOR], A; meta-analysis of randomized controlled trials [RCTs] including 1 large RCT). In adults with atherosclerotic CVD (ASCVD), the combination of ezetimibe and a moderate-intensity statin (rosuvastatin 10 mg) was noninferior at decreasing cardiovascular death, major cardiovascular events, and nonfatal stro...
Source: The Journal of Family Practice - June 20, 2023 Category: Practice Management Authors: Vinay Reddy James Allison Anne Mounsey Source Type: research
Position of the Polish Cardiac Society on therapeutic targets for LDL cholesterol concentrations in secondary prevention of myocardial infarctions
Kardiol Pol. 2023 Jul 25. doi: 10.33963/KP.a2023.0162. Online ahead of print.ABSTRACTCardiovascular diseases account for 43% of deaths in Poland. The COVID-19 pandemic increased the number of cardiovascular deaths by as much as 16.7%. Lipid metabolism disorders are observed in about 20 million Poles. Lipid disorders are usually asymptomatic, they cause a significant increase in the risk of cardiovascular diseases. Up to 20% of patients who experience an acute coronary syndrome (ACS) may experience a recurrence of a cardiovascular event within a year, and up to 40% of these patients may be re-hospitalized. Within 5 years af...
Source: Polish Heart Journal - July 25, 2023 Category: Cardiology Authors: Przemys ław Mitkowski Adam Witkowski Janina St ępińska Maciej Banach Piotr Jankowski Mariusz G ąsior Krystian Wita Stanis ław Bartuś Pawe ł Burchardt Micha ł M Farkowski Marek Gierlotka Robert Gil Przemys ław Leszek Maciej Sterli ński Piotr Szym Source Type: research
Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD?
J Fam Pract. 2023 Jun;72(5):227-229. doi: 10.12788/jfp.0610.ABSTRACTYES. In patients with known cardiovascular disease (CVD), ezetimibe with a statin decreases major adverse cardiovascular events (MACE) but has no effect on all-cause and cardiovascular mortality, compared to a statin alone (strength of recommendation [SOR], A; meta-analysis of randomized controlled trials [RCTs] including 1 large RCT). In adults with atherosclerotic CVD (ASCVD), the combination of ezetimibe and a moderate-intensity statin (rosuvastatin 10 mg) was noninferior at decreasing cardiovascular death, major cardiovascular events, and nonfatal stro...
Source: The Journal of Family Practice - June 20, 2023 Category: Practice Management Authors: Vinay Reddy James Allison Anne Mounsey Source Type: research
